Compare LMT & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LMT | BMY |
|---|---|---|
| Founded | 1912 | 1887 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 105.1B | 95.0B |
| IPO Year | N/A | N/A |
| Metric | LMT | BMY |
|---|---|---|
| Price | $473.59 | $53.78 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 15 | 13 |
| Target Price | ★ $512.07 | $56.31 |
| AVG Volume (30 Days) | 1.3M | ★ 15.5M |
| Earning Date | 01-27-2026 | 02-05-2026 |
| Dividend Yield | 2.89% | ★ 4.65% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 17.88 | 2.97 |
| Revenue | ★ $73,349,000,000.00 | $48,034,000,000.00 |
| Revenue This Year | $6.01 | $0.23 |
| Revenue Next Year | $4.23 | N/A |
| P/E Ratio | $26.68 | ★ $18.26 |
| Revenue Growth | ★ 2.88 | 1.26 |
| 52 Week Low | $410.11 | $42.52 |
| 52 Week High | $516.00 | $63.33 |
| Indicator | LMT | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 55.01 | 69.64 |
| Support Level | $455.88 | $50.33 |
| Resistance Level | $484.77 | $54.80 |
| Average True Range (ATR) | 9.41 | 1.18 |
| MACD | 3.68 | 0.29 |
| Stochastic Oscillator | 77.13 | 84.04 |
Lockheed Martin is the world's largest defense contractor and has dominated the Western market for high-end fighter aircraft since it won the F-35 Joint Strike Fighter program in 2001. Aeronautics is Lockheed's largest segment, which derives upward of two-thirds of its revenue from the F-35. Lockheed's remaining segments are rotary and mission systems, mainly encompassing the Sikorsky helicopter business; missiles and fire control, which creates missiles and missile defense systems; and space systems, which produces satellites and receives equity income from the United Launch Alliance joint venture.
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.